The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis
This study highlights NIV + IPI as a promising combination for advanced CRC, showing superior efficacy, while PEM also demonstrated potential. However, high heterogeneity suggests the need for further research. Acknowledging its limitations, this study marks a pioneering effort in comparing short- and long-term effects of anti-CTLA-4 and anti-PD-1 therapies, paving the way for future advancements in CRC treatment.
Authors
- Roy Novri Ramadhan (ORCID: https://orcid.org/0000-0001-6100-9015)
- Kevin Christian Tjandra (ORCID: https://orcid.org/0000-0003-3821-8446)
- Albertus Ari Adrianto (ORCID: https://orcid.org/0009-0000-0012-4845)
- Dewi Kartikawati Paramita (ORCID: https://orcid.org/0000-0001-6759-8658)
- Endang Mahati (ORCID: https://orcid.org/0000-0002-9101-8753)
- Gastin Gabriel Jangkang (ORCID: https://orcid.org/0000-0001-5327-0299)
- Danendra Rakha Putra Respati (ORCID: https://orcid.org/0009-0006-7725-8263)
- Derren David Christian Homenta Rampengan (ORCID: https://orcid.org/0009-0002-5482-0613)
- Patricia Winona
- Ignatius Riwanto
- Udadi Sadhana
- Henry Setyawan
Institutions
- Diponegoro University (ID)
- Atma Jaya Catholic University of Indonesia (ID)
- Universitas Gadjah Mada (ID)
- Universitas Airlangga (ID)
- Lambung Mangkurat University (ID)
- Sam Ratulangi University (ID)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1371/journal.pone.0307128
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05